Let’s cut to the chase: erectile dysfunction (ED) is a common issue, but it’s not the end of the world. Not even on Valentine ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health (NYSE:HIMS). And retail traders should know. We noticed this today when the trades showed up on publicly ...

If you’re on the fence about investing in Hims & Hers Health, Inc., Privia Health Group or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before ...

Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and ...

Millions of individuals around the world experience symptoms of erectile dysfunction (ED). But, for how common ED is, it can ...

According to another article on Hims’ Erectile Dysfunction page, treatments for erectile dysfunction are available starting at about $30 per month. This pricing allows customers to receive discreet ...

The millennial-focused digital health company Hims & Hers (HIMS) has donated $1 million to President-elect Donald Trump’s inauguration fund.

Hims & Hers is the latest company to donate ... spokesperson said in a statement obtained by Axios. In addition to erectile dysfunction treatment, the telehealth company has been a major player ...

BTIG initiated coverage of Hims & Hers with a Buy rating and $35 price target The firm says its likes Hims & Hers because of its “disruptive” business model approach that delivers health ...

It’s the great bate debate. The rising popularity of a solo sex act that may seem relatively harmless can have devastating effects on an intimate relationship with a partner, experts caution.